Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Journal
Lancet (London, England)
Journal Volume
401
Journal Issue
10388
Date Issued
2023-05-13
Author(s)
Heerspink, Hiddo J L
Radhakrishnan, Jai
Alpers, Charles E
Barratt, Jonathan
Bieler, Stewart
Diva, Ulysses
Inrig, Jula
Komers, Radko
Mercer, Alex
Noronha, Irene L
Rheault, Michelle N
Rote, William
Rovin, Brad
Trachtman, Howard
Trimarchi, Hernán
Wong, Muh Geot
Perkovic, Vlado
Abstract
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety.
Type
journal article